2nd Nov 2023 A plain language summary of the PALOMA-2 and PALOMA-3 studies: the effects of adding palbociclib to endocrine therapy to treat advanced breast cancer
6th Oct 2023 A plain language summary of the monarcHER study: abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer